Article thumbnail
Location of Repository

Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy

By Christos Markopoulos, Urania Dafni, John Misitzis, Vasilios Zobolas, Evagelos Tzoracoleftherakis, Dimitrios Koukouras, Grigorios Xepapadakis, John Papadiamantis, Basileios Venizelos, Zoh Antonopoulou and Helen Gogas
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2716503
Provided by: PubMed Central

Suggested articles

Citations

  1. (1995). A: Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
  2. (2007). Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev
  3. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat 2006, 100(suppl 1):S22. (#49, abstract)
  4. (2003). C: Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer
  5. (2005). Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet
  6. Clack G: Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Cancer Res Treat 2005, 94(suppl 1):S101. Abstract
  7. (1992). Coombes RC: Exemestane (FCE24304), a new steroidal aromatase inhibitor.
  8. (1992). Coombes RC: Phase I and endocrine study of exemestane (FCE24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res
  9. (1988). di Salle E: 6-Methylenandrosta-1,4-diene-3,17-dione (FCE24304): a new irreversible aromatase inhibitor.
  10. (1992). Dietary lipids and the low blood cholesterolcancer association.
  11. (1999). Drug Administration: Center for Drug Evaluation and Research application number NDA 20753 (Exemestane) Medical Review.
  12. (2005). EA: The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol
  13. (2004). for Chronic Disease Prevention and Health Promotion
  14. (2006). Gogas H: Duration of tamoxifen effect on lipidemic profile of postmenopausal breast cancer patients following deprivation of treatment. Oncology
  15. (2005). Gogas H: Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5–7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anticancer Drugs
  16. (2009). Gogas H: Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Ann Oncol
  17. (2005). Gogas H: The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat
  18. (2005). Goldhirsch A: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
  19. (2007). HJ: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol
  20. (1992). HRT: an analysis of benefits, risks, and costs. Br Med Bull
  21. (2005). JL: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
  22. (1996). Kesäniemi VA: Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women. Atherosclerosis
  23. (2002). La Vecchia C: Long-term mortality of women with a diagnosis of breast cancer. Oncology
  24. (2005). Massimini G: Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
  25. (1987). Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J
  26. (2004). MR: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptorpositive breast cancer: status report,
  27. NCCN: Clinical Practice Guidelines in Oncology™.
  28. (2005). on behalf of the ABCSG: Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol
  29. (1996). Pavlidis NA: The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property. Anticancer Res
  30. (1995). Plasma changes in breast cancer patients during endocrine therapy: lipid measurements and nuclear magnetic imaging (NMR) spectroscopy. Breast Cancer Res Treat
  31. (1982). Random effect models for longitudinal data. Biometrics
  32. (2008). randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive advanced breast cancer: results from EFECT. J Clin Oncol
  33. (1992). Rifkind B: Report of the Conference on Low Blood Cholesterol: mortality associations. Circulation
  34. (1999). Risks versus benefits in the clinical application of aromatase inhibitors. Endocr Relat Cancer
  35. (1994). RJ: Effects of tamoxifen on cardiovascular risk factors in postmenopausalAvailable online http://breast-cancer-research.com/content/11/3/R35
  36. (2006). S: Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.
  37. (1992). SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med
  38. (2005). Suman VJ: Aromatase inhibitors for therapy of advanced breast cancer.
  39. (2007). Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet
  40. (1993). TL: Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med
  41. (1997). Triglycerides and coronary risk in women and the elderly. Arch Intern Med
  42. (2004). Velde C van de: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
  43. (1999). Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.
  44. (2001). Wolmark N: Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.